Jade Biosciences, Inc. (JBIO)
NASDAQ: JBIO · Real-Time Price · USD
13.47
-0.29 (-2.11%)
Oct 16, 2026, 4:00 PM EDT - Market closed
Company Description
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases.
It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial.
The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.
Jade Biosciences, Inc.
| Country | United States |
| Founded | 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 55 |
| CEO | Tom Frohlich |
Contact Details
Address: Building 23, Suite 105 Waltham, Massachusetts 02453 United States | |
| Phone | 781 312 3013 |
| Website | jadebiosciences.com |
Stock Details
| Ticker Symbol | JBIO |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001798749 |
| CUSIP Number | 008064206 |
| ISIN Number | US0080642061 |
| Employer ID | 83-1377888 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Tom Frohlich | President, Chief Executive Officer and Director |
| Bradford D. Dahms Ph.D. | Chief Financial Officer and Treasurer |
| Dr. Andrew James King BVMS, D.V.M., Ph.D. | President of Research and Development |
| Elizabeth Balta J.D. | Chief Legal Officer and Corporate Secretary |
| Lori Stewart | Senior Vice President of People |
| Jonathan Quick | Senior Vice President of Finance |
| Valerie Fauvelle | Senior Vice President of Regulatory and Quality |
| Amy Sullivan | Senior Vice President of Development Operations |
| Sandy Lewis | Senior Vice President, Biometrics and Clinical Strategy |
| Dr. Edward R. Conner M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 30, 2026 | 8-K | Current Report |
| Aug 14, 2026 | SCHEDULE 13G/A | Filing |
| Aug 14, 2026 | SCHEDULE 13G/A | Filing |
| Aug 10, 2026 | 10-Q | Quarterly Report |
| Aug 10, 2026 | 8-K | Current Report |
| Jul 17, 2026 | SCHEDULE 13G | Filing |
| Jul 8, 2026 | SCHEDULE 13G/A | Filing |
| Jul 1, 2026 | 8-K | Current Report |
| Jun 26, 2026 | 8-K | Current Report |
| Jun 11, 2026 | 8-K | Current Report |